ARUP LABORATORIES | aruplab.com
500 Chipeta Way, Salt Lake City, Utah 84108-1221
phone: 801-583-2787, toll free: 800-522-2787
Jonathan R. Genzen, MD, PhD, Chief Medical Officer

PATIENT REPORT

Patient Age/Sex: 42 years Male

Specimen Collected: 10/15/2024 09:00 MDT

KLHL11 Antibody, IgG by CBA-IFA, Serum | **Received: 10/16/2024 11:57 MDT** | **Report/Verified: 10/23/2024 22:14 MDT**

Procedure	Result	Units	Reference Interval
KLHL11 Ab IgG CBA-IFA Screen, Serum	**Detected** * t1 i1		[<1:10]

KLHL11 Ab IgG CBA-IFA Titer, Serum | **Received: 10/16/2024 11:57 MDT** | **Report/Verified: 10/23/2024 22:14 MDT**

Procedure	Result	Units	Reference Interval
KLHL11 Ab IgG CBA-IFA Titer, Serum	**>1:2560** * i2		[<1:10]

Interpretive Text

t1: 10/15/2024 09:00 MDT (KLHL11 Ab IgG CBA-IFA Screen, Serum)
KLHL11 Antibody, IgG is detected. Titer results to follow.

Test Information

i1: KLHL11 Ab IgG CBA-IFA Screen, Serum
INTERPRETIVE INFORMATION: KLHL11 Antibody, IgG by CBA-IFA, Serum
IgG antibodies to KLHL11 are associated with paraneoplastic neurologic syndromes with phenotypes most often including a combination of brainstem and cerebellar encephalitis as well as sensorineural hearing loss. Patients with anti-KLHL11 syndromes should be thoroughly evaluated for cancer, including testicular cancer, as neurologic symptoms often precede cancer diagnosis. Consider sending testing in CSF as well as serum to improve diagnostic yield. Coexisting and clinically relevant antineural antibodies have been reported; consider ordering a phenotype-specific panel to assess for these. Results (positive or negative) should be interpreted in the context of the patient's complete clinical picture, as false positives may occur, and a negative result does not exclude the diagnosis of immune-mediated neurologic disease.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

i2: KLHL11 Ab IgG CBA-IFA Titer, Serum
INTERPRETIVE INFORMATION: KLHL11 Ab IgG CBA-IFA Titer, Serum
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab